Investors in nanocap Cesca Therapeutics (KOOL) have not had much of a good time:
Not surprising given that revenue has gone south and the company produces large losses:
YCharts
The company's device segment ThermoGenesis is selling automated medical devices and technologies for cell-based therapies, including stem cell banking, point-of-care applications and large-scale cellular manufacturing of immunotherapy drugs, including chimeric antigen receptor t-cells or the CAR-T cells. Its main solutions are:
- AutoXpress or AXP (stem cell banking and storage)
- AXP II (improved version of AXP)
- POCXpress or PXP (automated cell processing of